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A B S T R A C T
Objectives: The aim of this study was to assess colistin use in a country endemic for multidrug-resistant
Gram-negative bacteria (MDR-GNB).
Methods: Colistin prescription patterns were evaluated in 22 Italian centres. Factors associated with use
of colistin in combination with other anti-MDR-GNB agents were also assessed.
Results: A total of 221 adults receiving colistin were included in the study. Their median age was 64 years
(interquartile range 52–73 years) and 134 (61%) were male. Colistin was mostly administered
intravenously (203/221; 92%) and mainly for targeted therapy (168/221; 76%). The most frequent
indications for colistin therapy were bloodstream infection and lower respiratory tract infection.
Intravenous colistin was administered in combination with at least another anti-MDR-GNB agent in 80%
of cases (163/203). A loading dose of 9 MU of colistimethate was administered in 79% of patients receiving
i.v. colistin and adequate maintenance doses in 85%. In multivariable analysis, empirical therapy [odds
ratio (OR) = 3.25, 95% confidence interval (CI) 1.24–8.53;P = 0.017] and targeted therapy for carbapenem-
resistant Enterobacterales infection (OR = 4.76, 95% CI 1.69–13.43; P = 0.003) were associated with use of
colistin in combination with other agents, whilst chronic renal failure (OR = 0.39, 95% CI 0.17–0.88; P =
0.024) was associated with use of colistin monotherapy.
Conclusion: Colistin remains an important option for severe MDR-GNB infections when other treatments
are not available. Despite inherent difficulties in optimising its use owing to peculiar pharmacokinetic/
pharmacodynamic characteristics, colistin was mostly used appropriately in a country endemic for MDR-
GNB.
© 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Colistin, a polymyxin antibiotic, is a last-resort treatment
option for multidrug-resistant Gram-negative bacteria (MDR-
GNB), especially carbapenem-resistant Enterobacterales (CRE)
and non-fermenters [1–3].
Despite the fact that a reduction in its use will likely be
observed in the near future owing to the recent marketing of
several novel agents, colistin still remains among the few
potentially active treatment options for carbapenem-resistant
Acinetobacter baumannii (CRAB) and for other MDR-GNB resistant
to novel compounds [1,2,4–6]. Very importantly, use of colistin
should be reserved for these indications and should be avoided in
the presence of dependable alternatives, since its effectiveness and
safety can be impaired by several factors, including: (i) narrow
therapeutic index, which may result in either suboptimal
concentrations or nephrotoxicity [7]; (ii) suboptimal concentra-
tions in lung tissue [8]; (iii) frequent unavailability of colistin
therapeutic drug monitoring outside of research laboratories; and
(iv) unintended treatment of colistin-resistant infections owing to
possible limitations of some classical susceptibility testing
methods [9]. Therefore, using colistin appropriately (e.g. correct
indication, correct dosage, reserving it for infections caused by, or
strongly suspected to be caused by, MDR-GNB) is certainly difficult
but is of paramount importance for improving patient outcomes
and relieving selective pressure due to suboptimal dosages on
those strains for which colistin remains, or may remain, the only
active therapeutic option.
Although several studies evaluating the use of colistin for
selected MDR-GNB infections have been conducted over the last
decades [3,6,10,11], little is known about the overall character-
istics of colistin use in countries endemic for MDR-GNB. In light
of this, assessing colistin prescription patterns is a fundamental
step for ultimately tailoring antimicrobial stewardship inter-
ventions in order both to optimise colistin use and to preserve
its activity in the long-term. In this cross-sectional study,
prescription patterns of colistin in adult patients in Italy, a
country endemic for MDR-GNB, especially CRE and CRAB [12],
were assessed.2. Materials and methods
2.1. Study design and objectives
This observational, cross-sectional study was conducted in 22
Italian centres [20 hospitals plus 2 intensive care units (ICUs)]. The
complete list of participating centres is available in Supplementary
Table S1, whilst their geographical distribution is shown in Fig. 1.
The study was first approved by the Ethics Committee of the co-
ordinating centre (Ospedale Policlinico San Martino–IRCCS, Genoa,
Italy) and subsequently by the Ethics Committees of the other 21
participating centres. After receiving approval from the pertinent
local ethics committee, all adult patients starting colistin
treatment during a consecutive 3-month period were prospec-
tively included in the study. The 3-month enrolment period started
in March 2018 in the first activated centre and finished in
September 2018 in the last activated centre. Data were collected at
the time of colistin initiation with no follow-up, in line with the
cross-sectional design and the objectives of the study. All
conscious patients signed an informed consent to participate in
the study. A waiver of informed consent for patients unconscious at
the time of colistin initiation was obtained in most participating
centres (only five unconscious patients were not enrolled).
Patients were included in the study only once, at the time of
initiation of the first colistin treatment during the study period.
The primary objective of the study was to describe the use of
colistin in terms of dosages, indications and characteristics of
treated patients. The secondary objective was to assess factors
associated with the use of colistin in combination with other anti-
MDR-GNB agents. Details regarding protocol registration and
deviations, sample size calculation and statistical analysis are
available in the Supplementary methods.
3. Results
During the study period, 229 adult patients received colistin
treatment, of whom 221 (97%) were included in the study
(Supplementary Fig. S1). Their median age was 64 years
(interquartile range 52–73 years) and 134 (61%) were male.
Fig. 1. Geographical distribution of participating centres. A detailed list of the 22 participating centres is available as Supplementary Table S1.
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characteristics of the enrolled patients. Of the 221 patients, 32
(14%) had received a previous course of colistin therapy, mostly in
combination with other anti-MDR-GNB agents (29/30; 97%).
Previous colonisation/infection with at least one carbapenem-
resistant organism [CRE, carbapenem-resistant Pseudomonas
aeruginosa (CRPA) or CRAB] was registered in 62% of patients
(138/221), with a 12% (15/121) prevalence of colistin resistance in
previous isolates.
Colistin was mostly administered intravenously (203/221; 92%)
and mainly for targeted therapy (168/221; 76%). Among 203 cases
of intravenous (i.v.) administration, colistin was concomitantly
administered as inhaled (20/203; 10%) or intrathecal (3/203; 1%)
therapy (Supplementary Table S2). The most frequent indications
for colistin administration were sepsis and lower respiratory tract
infection (LRTI) for empirical therapy and bloodstream infection
(BSI) and LTRI for targeted therapy (Supplementary Table S2).
Among 53 cases of empirical therapy, 48 (91%) had a history of
previous colonisation/infection by a carbapenem-resistant organ-
ism in the patient and/or in other patients hospitalised in the same
ward. After starting empirical colistin, an aetiological diagnosis
was achieved in 30/53 patients (57%) and CRE, CRAB and CRPAwere isolated in 33% (10/30), 30% (9/30), and 7% (2/30) of cases,
respectively. CRAB was the most frequent causative agent of
infections treated with targeted colistin, being involved as
monomicrobial or polymicrobial infections in as many as 85/168
cases (51%). The complete list of aetiological agents is available as
Supplementary Table S3.
Colistin susceptibility testing was performed on 183/198 (92%)
causative isolates obtained either before or after colistin initiation,
mostly using automated systems (145/183; 79%). Broth micro-
dilution as first susceptibility test method or as confirmatory test
was performed in 124/183 cases (68%). Gradients tests were
employed in 4/183 cases (2%), and in all of them with subsequent
broth microdilution confirmation. Colistin susceptibility in causa-
tive agents isolated after initiation of empirical colistin was
assessed in 15 cases, of which 4 (27%) were colistin-resistant.
Intravenous colistin was administered in combination with at
least one other anti-MDR-GNB agent in 80% of cases (163/203). A
loading dose of 9 million units (MU) of colistimethate was
administered in 79% of patients receiving i.v. colistin, whereas
adherence to the European Medicines Agency (EMA) Committee
for Medicinal Products for Human Use (CHMP) recommendations
[13] for prescribed maintenance dosages was 85% (Table 2).
Table 1
Demographic and clinical characteristics of adult patients treated with colistin.
Variable No. of patientsa % 95% CI
Demographic characteristics
Age (years) [median (IQR)] 64 (52–73) 62–67
Male sex 134/221 61 54–67
Medical history
Previous hospitalisation (within 6 months) 124/221 56 49–63
Diabetes mellitus 55/221 25 19–31
Chronic renal failure 45/221 20 15–26
Solid neoplasm 40/221 18 13–24
Haematological malignancy 16/221 7 4–11
Charlson comorbidity index [median (IQR)] 2 (1–3) 2–2
Previous treatment with colistinb 32/221 15 10–20
Anti-MDR-GNB monotherapy 1/30 3 0–16
Anti-MDR-GNB combination therapy 29/30 97 84–100
Unknown whether monotherapy or combination 2/32
Hospital stay before colistin initiation (days) [median (IQR)] 21 (10–43) 17–25
Microbiological history
Previous colonisation/infection by CRE
In the patient 89/221 40 34–47
Colistin-resistant 8/77 10 5–19
(Colistin not tested) (12)
In other patients in the same ward c 142/221 64 58–70
Colistin-resistant 26/135 19 13–27
(Colistin not tested) (7)
Previous colonisation/infection by CRPA
In the patient 17/221 8 5–12
Colistin-resistant 0/16 0 0–2
(Colistin not tested) (1)
In other patients in the same wardc 32/221 15 10–20
Colistin-resistant 3/31 10 3–25
(Colistin not tested) (1)
Previous colonisation/infection by CRAB
In the patient 55/221 25 19–31
Colistin-resistant 7/50 14 6–27
(Colistin not tested) (5)
In other patients in the same wardc 94/221 43 36–49
Colistin-resistant 15/94 16 10–25
(Colistin not tested) (0)
Previous colonisation/infection by CRE, CRPA and/or CRAB
In the patient 138/221 62 56–69
Colistin-resistant 15/121 12 7–20
(Colistin not tested) (17)
In other patients in the same wardc 165/221 75 68–80
Colistin-resistant 39/158 25 18–32
(Colistin not tested) (7)
Baseline variablesc
Ward
ICU 96/221 43 37–50
Medical ward 80/221 36 30–43
Surgical ward 33/221 15 11–20
Rehabilitation ward 12/221 5 3–9
Presence of CVC 165/221 75 68–80
Presence of urinary catheter 179/221 81 75–86
Mechanical ventilation 66/221 30 24–36
Septic shock 43/221 19 15–25
Neutropenia 14/221 6 4–10
Serum albumin (g/dL) [median (IQR)]d 2.6 (2.3–3.0) 2.6–2.8
Missing (serum albumin not tested) 22/221
Serum creatinine (mg/dL) [median (IQR)]d 0.8 (0.6–1.3) 0.7–0.9
Haemodialysis 15/221 7 4–11
KDIGO stage of AKI
No AKI 170/221 77 71–82
Stage 1 24/221 11 7–16
Stage 2 12/221 5 3–9
Stage 3 15/221 7 4–11
AKI, acute kidney injury; CI, confidence interval; CRAB, carbapenem-resistant Acinetobacter baumannii; CRE, carbapenem-resistant Enterobacterales; CRPA, carbapenem-
resistant Pseudomonas aeruginosa; CVC, central venous catheter; ICU, intensive care unit; IQR, interquartile range; KDIGO, Kidney Disease: Improving Global Outcomes; MDR-
GNB, multidrug-resistant Gram-negative bacteria.
a Results are presented as no. of patients/total of patients unless otherwise stated.
b Previous anti-MDR-GNB combination was defined as previous treatment with colistin in combination with at least one of the following agents: carbapenems;
aminoglycosides; fosfomycin; tigecycline; trimethoprim/sulfamethoxazole; rifampicin; ceftazidime/avibactam; and ceftolozane/tazobactam.
c At the time of colistin initiation.
d Last measured value before colistin initiation.
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Table 2
Characteristics of intravenous colistin therapies.
Variable No. of patientsa % 95% CI
Type of therapy
Empirical therapy 49/203 24 19–30
Targeted therapyb 154/203 76 70–81
Type of anti-MDR-GNB therapy
Colistin monotherapy 40/203 20 15–26
Combination therapyc 163/203 80 74–85
Targeted therapy for CREd
Colistin monotherapy 4/40 10 3–23
Combination therapye 36/40 90 77–97
Targeted therapy for CRPAd
Colistin monotherapy 7/22 32 15–55
Combination therapye 15/22 68 45–85
Targeted therapy for CRABd
Colistin monotherapy 21/65 32 22–45
Combination therapy e 44/65 68 55–78
Dosage
Administration of loading dose 178/203 88 82–92
Administration of loading dose of 9 MU of CMSf 160/203 79 73–84
Adequate daily maintenance dosage of CMS according
to estimated CLCrg,h [20]
All patients 159/187 85 79–90
CLCr 10 to <30 mL/min (4.50–5.50 MU) 13/18 72 47–88
CLCr 30 to <50 mL/min (5.50–7.50 MU) 14/22 64 42–81
CLCr  50 mL/min (9.00 MU) 132/147 90 84–94
CI, confidence interval; CLCr, creatinine clearance; CMS, colistimethate; CRAB, carbapenem-resistant Acinetobacter baumannii; CRE, carbapenem-resistant Enterobacterales;
CRPA, carbapenem-resistant Pseudomonas aeruginosa; EMA CHMP, European Medicines Agency Committee for Medicinal Products for Human Use; IQR, interquartile range;
MDR-GNB, multidrug-resistant Gram-negative bacteria; MU, million units.
a Results are presented as no. of patients/total of patients unless otherwise stated. The denominator (n = 203) includes intravenous (n = 180), intravenous plus inhaled
(n = 20) and intravenous plus intrathecal (n = 3) colistin therapies.
b Post-identification of the causative agent.
c Anti-MDR-GNB combination was defined as treatment with colistin in combination with at least one of the following agents: carbapenems; aminoglycosides; fosfomycin;
tigecycline; trimethoprim/sulfamethoxazole; rifampicin; ceftazidime/avibactam; ceftolozane/tazobactam; and any other anti-Gram-negative agent administered in
combination with colistin for the intended treatment of a suspected or proven MDR-GNB infection.
d Analyses limited to monomicrobial infections due to CRE, CRPA or CRAB.
e Colistin companion agents for CRE infections: meropenem (n = 11); fosfomycin + meropenem (n = 5); fosfomycin + tigecycline (n = 4); meropenem + tigecycline (n = 3);
tigecycline (n = 3); fosfomycin (n = 2); gentamicin + meropenem (n = 2); amikacin + ceftazidime/avibactam + tigecycline (n = 1); ceftazidime/avibactam (n = 1); ceftazi-
dime + levofloxacin (n = 1); ceftazidime/avibactam + meropenem (n = 1); ertapenem + meropenem (n = 1); and gentamicin + tigecycline (n = 1). Colistin companion agents for
CRPA infections: meropenem (n = 6); ceftolozane/tazobactam (n = 3); amikacin (n = 1); amikacin + meropenem (n = 1); ceftazidime/avibactam (n = 1); ceftolozane/
tazobactam + meropenem (n = 1); imipenem (n = 1); piperacillin/tazobactam (n = 1). Colistin companion agents for CRAB infections: meropenem (n = 15); merope-
nem + tigecycline (n = 5); rifampicin (n = 5); tigecycline (n = 4); ampicillin/sulbactam + meropenem (n = 2); rifampicin + tigecycline (n = 2); amikacin (n = 1); ampicillin/
sulbactam (n = 1); ampicillin/sulbactam + rifampicin (n = 1); cefepime (n = 1); ceftolozane/tazobactam + tigecycline (n = 1); trimethoprim/sulfamethoxazole + tigecycline
(n = 1); fosfomycin + meropenem + rifampicin + tigecycline (n = 1); gentamicin + meropenem (n = 1); imipenem (n = 1); and meropenem + rifampicin (n = 2).
f As recommended by the EMA CHMP both in patients with and without impaired renal function, including those receiving renal replacement therapy [13].
g In patients not receiving haemodialysis (188/203). Maintenance dose information missing for 1 patient (final denominator = 187). The last two serum creatinine values
before colistin initiation were collected to estimate CLCr according to the Jelliffe formula.
h Overall, 184/203 patients treated with intravenous colistin therapy (91%) received maintenance dosages in two daily doses.
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septic shock, empirical therapy, targeted therapy for CRE infections
and i.v. administration showed a statistically significant associa-
tion with the use of colistin in combination, whereas chronic renal
failure and targeted therapy of CRAB infections were associated
with use of colistin monotherapy (Supplementary Table S4). In the
multivariable analysis (model A), only empirical therapy [odds
ratio (OR) = 3.25, 95% confidence interval (CI) 1.24–8.53; P = 0.017],
targeted therapy for CRE infections (OR = 4.76, 95% CI 1.69–13.43;
P = 0.003) and chronic renal failure (OR = 0.39, 95% CI 0.17–0.88;
P = 0.024) retained statistically significant associations (Supple-
mentary Table S5). Supplementary Table S5 also shows the results
of the additional multivariable model with centre as a random
effect (model B), which largely confirmed the associations
observed in model A (although with borderline significance for
chronic renal failure, possibly because of reduced power), but also
indicated i.v. administration as a further variable associated with
combination therapy.
4. Discussion
In a cohort of 221 patients from 22 Italian centres, colistin was
mostly used intravenously and in combination with other anti-MDR-GNB agents, mainly for the targeted therapy of LRTIs and BSIs
caused by carbapenem-resistant organisms.
Use of colistin in the USA and Europe has recently been
explored by Wenzler et al. with an electronic questionnaire survey
distributed to 420 physicians asking about their routine use of
colistin [14]. The respondents indicated that they administer
polymyxins mainly for pneumonia (63%) and for suspected/proven
carbapenem-resistant infections (85%) [14], which is in line with
the current findings. In addition, the current study also directly
measured the actual proportion of empirical use of colistin, which
was 24% versus 76% for targeted therapy. Of note, this preference
towards restricting the use of colistin for targeted therapy, possibly
relying on the intention of avoiding nephrotoxic agents in
empirical therapy, could theoretically help to delay the emergence
of colistin resistance. It is also worth noting that on no occasion
was colistin used for selective digestive decontamination, possibly
reflecting the intention to avoid further selective pressure for
resistance in a country already endemic for CRE [15–17].
In the present study, the level of adequateness of i.v. colistin
dosages was measured according to the EMA CHMP review of
polymyxin-based medicines [13], observing a high proportion both
of adequate loading doses (79%) and adequate maintenance
dosages (85%). These results are in line with the fact that
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use of this last-resort agent have been already implemented in
Italian hospitals [18], but they also clearly identify specific points
where further improvements are still needed, mainly tailored
interventions for reducing the missing 21% of adequate loading
dosage. In addition, it should be noted that international consensus
guidelines regarding the optimal use of polymyxins have been
published very recently (after performance of the present study)
that indicate the possible need for increased maintenance dosages
in patients with creatinine clearance >80 mL/min, in line with the
most recent pharmacokinetic/pharmacodynamic evidence [19]. If
validated in confirmatory studies, this will likely become common
practice in the future in order not to risk suboptimal exposures in
patients without renal function impairments [19].
Most patients in this study received colistin as part of a
combination for the treatment of a suspected or proven infection
due to MDR-GNB. In this regard, the possible survival benefit of
using combinations for treating severe CRE infections, previously
reported in observational studies [10], might contribute to
explaining the independent association found between use of
colistin in combination and both targeted therapy of CRE and
empirical therapy (need for CRE coverage). None the less, although
less frequently than for CRE infections, it is worth noting that
colistin was also mainly used in combinations for treating CRPA
and CRAB (e.g. as i.v. treatment, combined regimens were
preferred to monotherapy in 90% of monomicrobial CRE infections
but also in 68% of monomicrobial CRPA infections and 68% of
monomicrobial CRAB infections). On the one hand, the non-
negligible proportion of patients with CRPA and CRAB treated with
combinations may be in line with the intention of clinicians to deal
with the possible suboptimal pharmacokinetics of colistin by
adding another agent, hoping for synergy or just for additive
effects. On the other hand, the reduced use of combinations for
CRPA and CRAB in comparison with CRE possibly reflects the lack of
evidence for CRPA (only a few small observational studies
exploring the use of colistin-based combinations for CRPA have
been conducted) and the results of the AIDA randomised
controlled trial for CRAB [2]. In this latter study, Paul et al. found
that addition of meropenem to colistin did not reduce the rate of
clinical failure in patients with severe CRAB infections, thus casting
doubts about the use of colistin plus meropenem combinations for
CRAB [2]. However, it is of note that carbapenems were employed
in as much as 61% of colistin-based combinations used for CRAB
infections in the current study, possibly reflecting the lack of other
therapeutic options [20].
With regard to other factors associated with use of colistin in
combination or as monotherapy in this study, the association
found between chronic renal failure and monotherapy may partly
depend on the unwillingness to combine colistin with other
nephrotoxic agents (i.e. aminoglycosides), even when they remain
the only other dependable option. The association between i.v.
administration and use in combination found in the additional
mixed multivariable model may reflect the preferential use of
combinations for treating severe infections, which usually require
i.v. therapy.
The present study has some limitations. The first is that follow-
up data were not collected, thus rates of clinical response to colistin
treatment and survival could not be assessed. However, the main
aim was to focus on the characteristics of colistin prescription
patterns and the study was thus designed to optimise the
collection of cross-sectional descriptive data (e.g. for adequately
describing the heterogeneity in colistin treatment) rather than for
assessing the impact on outcome of colistin therapy (where
heterogeneity usually implies considerable confounding effects).
Another limitation is that we were unable to register detailed data
on the type of haemodialysis (e.g. intermittent haemodialysis,sustained low-efficiency dialysis, continuous renal replacement
therapy). Consequently, the adequateness of maintenance dosages
in the 15 patients who received haemodialytic treatment could not
be evaluated. It should also be noted that despite the large sample
size, peculiar characteristics of some participating centres (e.g. two
participated only as ICUs, one centre is specialised in solid-organ
transplants, and another one is specialised in neurorehabilitation)
might partly limit the generalisability of the results. Finally, no
phenotypic or molecular information regarding carbapenem and
colistin resistance determinants was collected.
In conclusion, colistin remains an important option for severe
MDR-GNB infections when other options are not available. Colistin
was mostly used appropriately according to recommendations
available at the time of the study in a country endemic for MDR-
GNB organisms, although the results also indicate that targeted
efforts might be necessary for further increasing the rate of
adequate loading dosages. The recent availability and dissemina-
tion of international consensus guidelines based on updated
information might further improve the use of this last-resort drug
in the future.
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